Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris’ (PHVS) Investment Narrative?

• Pharvaris N.V. reported full-year 2025 results, posting a net loss of €175.7 million and a basic loss per share from continuing operations of €2.97, widening from the prior year.

• Alongside these results, the company highlighted progress in its hereditary angioedema pipeline, including completed Phase 3 enrollment and confirmed plans to file a New Drug Application for deucrictibant immediate-release in the first half of 2026.

• We will now examine how Pharvaris's completed Phase 3 enrollment for deucrictibant shapes the company's broader investment narrative and risk profile.

Outshine the giants: these 21 early-stage AI stocks could fund your retirement .

What Is Pharvaris' Investment Narrative?

To own Pharvaris today, you have to believe that its deucrictibant franchise can eventually justify years of zero revenue and steadily rising losses, including the recent €175.7 million annual net loss. The completed Phase 3 enrollment for the CHAPTER-3 prophylaxis study matters because it locks in a clear sequence of near-term catalysts around deucrictibant: the planned New Drug Application filing for the immediate-release, on-demand capsule in the first half of 2026, followed by CHAPTER-3 topline data later in the year. This reduces execution risk around trial recruitment but does not change the core binary nature of upcoming readouts or the funding demands of an early-stage, loss-making biotech. The recent share price strength suggests the market is already assigning meaningful value to those milestones.

However, the widening losses and ongoing cash needs are something investors should be very clear about.Pharvaris' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be .

Exploring Other Perspectives

The single fair value estimate from the Simply Wall St Community sits at €46.24 per share, above recent trading. Against that optimism, the larger 2025 net loss and lack of revenue keep execution and financing risks firmly in focus, which could meaningfully influence how the story plays out from here. Investor opinions can differ widely, so it is worth weighing several viewpoints before deciding what Pharvaris is worth to you.

Explore another fair value estimate on Pharvaris - why the stock might be worth just $46.24!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pharvaris research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.

• Our free Pharvaris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pharvaris' overall financial health at a glance.